New Delhi, Mar 28 (PTI) Aurobindo Pharma on Thursday said the deadline for negotiations between its arm CuraTeQ Biologics and Merck Sharp & Dohme Singapore for contract manufacturing operations for biologicals has been extended till May next year. Last year in October, CuraTeQ Biologics Pvt Ltd and Merck Sharp & Dohme Singapore Trading Pte Ltd and its affiliates (MSD) had signed a letter of intent (LoI) for contract manufacturing operations (CMO) for biologicals, whereby the parties intended to conclude the negotiations by March 31, 2024. Also Read | Good Friday 2024 FAQs: Is Stock Market Open or Closed on Good Friday? Is There a Bank Holiday on Good Friday? Here’s All You Need To Know. “In this regard, we further…
Published Date: 2024-03-28
Source: LatestLY
Categories: Business, Biotechnology and Pharmaceuticals, Pharmaceuticals, Society, Issues, Science, Technology, Structural Engineering, Major Companies
